KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Equity Average: 2011-2025

Historic Equity Average for Sarepta Therapeutics (SRPT) over the last 13 years, with Sep 2025 value amounting to $1.3 billion.

  • Sarepta Therapeutics' Equity Average rose 16.51% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 16.51%. This contributed to the annual value of $1.2 billion for FY2024, which is 91.84% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Equity Average of $1.3 billion as of Q3 2025, which was up 7.10% from $1.3 billion recorded in Q2 2025.
  • Sarepta Therapeutics' Equity Average's 5-year high stood at $1.4 billion during Q4 2024, with a 5-year trough of $407.9 million in Q4 2022.
  • Over the past 3 years, Sarepta Therapeutics' median Equity Average value was $1.0 billion (recorded in 2024), while the average stood at $1.0 billion.
  • Per our database at Business Quant, Sarepta Therapeutics' Equity Average plummeted by 53.35% in 2021 and then skyrocketed by 99.03% in 2023.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Equity Average stood at $698.8 million in 2021, then plummeted by 41.63% to $407.9 million in 2022, then soared by 99.03% to $811.8 million in 2023, then skyrocketed by 69.29% to $1.4 billion in 2024, then climbed by 16.51% to $1.3 billion in 2025.
  • Its Equity Average was $1.3 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.3 billion in Q1 2025.